The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
N ‐acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: A randomized, double‐blind, placebo‐controlled trial
Open accessAbstract
Objective: Systemic lupus erythematosus (SLE) patients exhibit T cell dysfunction, which can be regulated through mitochondrial transmembrane potential (Δψm) and mammalian target of rapamycin (mTOR) by glutathione (GSH). This randomized, double‐blind, placebo‐controlled study was undertaken to examine the safety, tolerance, and efficacy of the GSH precursor N ‐acetylcysteine (NAC). Methods: A total of 36 SLE patients received either daily placebo or 1.2 gm, 2.4 gm, or 4.8 gm of NAC. Disease activity was evaluated monthly by the British Isles Lupus Assessment Group (BILAG) index, the SLE Disease Activity Index (SLEDAI), and the Fatigue Assessment Scale (FAS) before, during, and after a 3‐month treatment period. Mitochondrial transmembrane potential and mTOR were assessed by flow cytometry. Forty‐two healthy subjects matched to patients for age, sex, and ethnicity were studied as controls. Results: NAC up to 2.4 gm/day was tolerated by all patients, while 33% of those receiving 4.8 gm/day had reversible nausea. Placebo or NAC 1.2 gm/day did not influence disease activity. Considered together, 2.4 gm and 4.8 gm NAC reduced the SLEDAI score after 1 month ( P = 0.0007), 2 months ( P = 0.0009), 3 months ( P = 0.0030), and 4 months ( P = 0.0046); the BILAG score after 1 month ( P = 0.029) and 3 months ( P = 0.009); and the FAS score after 2 months ( P = 0.0006) and 3 months ( P = 0.005). NAC increased Δψm ( P = 0.0001) in all T cells, profoundly reduced mTOR activity ( P = 0.0009), enhanced apoptosis ( P = 0.0004), reversed expansion of CD4−CD8− T cells (mean ± SEM 1.35 ± 0.12‐fold change; P = 0.008), stimulated FoxP3 expression in CD4+CD25+ T cells ( P = 0.045), and reduced anti‐DNA production ( P = 0.049). Conclusion: This pilot study suggests that NAC safely improves lupus disease activity by blocking mTOR in T lymphocytes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dietary supplementation with N-acetylcysteine (a precursor of glutathione) inhibits the mTOR pathway, restores the mitochondrial membrane potential and increases the mitochondrial mass in lymphocytes from patients with SLE85,86”
From The role of mitochondria in rheumatic diseases (2022) · cites this paper as [85]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, mTOR blockade in patients with SLE treated with N-acetylcysteine or rapamycin reduces both pro-inflammatory T cells and disease activity85,260, suggesting that dietary supplementation or drugs that regulate mitochondrial dynamics might constitute novel therapeutic avenues for mitigating autoantibody production in SLE.”
From The role of mitochondria in rheumatic diseases (2022) · cites this paper as [85]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
Derivation of the sledai. A disease activity index for lupus patients
Bombardier, C., Gladman, D. D., Urowitz, M. B., Caron, D., Chang, C. H., Austin, A., Bell, A., Bloch, D. A., Corey, P. N., Decker, J. L., et al. (1992) · Arthritis & Rheumatism · doi:10.1002/art.1780350606 · Cited by 4,570
High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis
Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H. M., MacNee, W., Thomeer, M., Wallaert, B., Laurent, F., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042976 · Cited by 964
Psychometric qualities of a brief self-rated fatigue measure
Michielsen, H. J., De Vries, J., & Van Heck, G. L. (2003) · Journal of Psychosomatic Research · doi:10.1016/s0022-3999(02)00392-6 · Cited by 860
Crispín, J. C., Oukka, M., Bayliss, G. P., Cohen, R. A., van Beek, C., Stillman, I. E., Kyttaris, V. C., Juang, Y., & Tsokos, G. C. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.12.8761 · Cited by 800
Battaglia, M., Stabilini, A., Migliavacca, B., Horejs‐Hoeck, J., Kaupper, T., & Roncarolo, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.12.8338 · Cited by 746
Glutathione deficiency is associated with impaired survival in HIV disease
Herzenberg, L. A., Rosa, S. C. D., Dubs, J. G., Roederer, M., Anderson, M. T., Ela, S. W., Deresinski, S. C., & Herzenberg, L. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.5.1967 · Cited by 672
Isenberg, D. A., Rahman, A., Allen, E., Farewell, V. T., Akil, M., Bruce, I. N., D’Cruz, D. P., Griffiths, B., Khamashta, M. A., Maddison, P. J., et al. (2005) · Lara D. Veeken · doi:10.1093/rheumatology/keh624 · Cited by 638
Valencia, X., Yarboro, C. H., Illei, G. G., & Lipsky, P. E. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.4.2579 · Cited by 590
Quantification of regulatory T cells in patients with systemic lupus erythematosus
Crispín, J. C., Martínez, A. A., & Alcocer-Varela, J. C. (2003) · Journal of Autoimmunity · doi:10.1016/s0896-8411(03)00121-5 · Cited by 406
Flagged first, then by citations
Research works printed but not linked: 1
- Lai Z, 2010, Reversal of CD3+/CD4+/CD25+/Foxp3+ Treg depletion in active SLE patients with rapamycin, Arthritis Rheum, 62, S501
Cited by
Sorted by citations
Items 101–200 of 427
Liu, Y., Yu, J., Oaks, Z., Marchena, I., Francis, L., Bonilla, E., Aleksiejuk, P. A., Patel, J., Bánki, K., LANDAS, S. K., et al. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.07.001 · Cited by 57
Self-citationMetabolism as a key regulator in the pathogenesis of systemic lupus erythematosus
Takeshima, Y., Iwasaki, Y., Fujio, K., & Yamamoto, K. (2019) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2019.04.006 · Cited by 57
Tsai, C., Shen, C., Liao, H., Li, K., Lee, H.-T., Lu, C.-S., Wu, C.-H., Kuo, Y., Hsieh, S., & Yu, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20163878 · Cited by 58
Histone Deacetylation Inhibitors as Modulators of Regulatory T Cells
von Knethen, A., Heinicke, U., Weigert, A., Zacharowski, K. D., & Brüne, B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072356 · Cited by 59
Endometriosis and autoimmunity
Blanco, L. P., Salmeri, N., Temkin, S. M., Shanmugam, V. K., & Stratton, P. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103752 · Cited by 59
Autophagy: A new concept in autoimmunity regulation and a novel therapeutic option
Bonam, S. R., Wang, F., & Muller, S. (2018) · Journal of Autoimmunity · doi:10.1016/j.jaut.2018.08.009 · Cited by 55
Fatigue Measurements in Systemic Lupus Erythematosus
Barbacki, A., Petri, M., Aviña-Zubieta, A., Alarcón, G. S., & Bernatsky, S. (2019) · The Journal of Rheumatology · doi:10.3899/jrheum.180831 · Cited by 53
Basic mechanism of immune system activation by mitochondria
Iwasaki, Y., Takeshima, Y., & Fujio, K. (2020) · Immunological Medicine · doi:10.1080/25785826.2020.1756609 · Cited by 53
Differential impact of environmental factors on systemic and localized autoimmunity
Touil, H., Mounts, K., & Jager, P. L. D. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1147447 · Cited by 57
The Role of Immunometabolism in the Pathogenesis of Systemic Lupus Erythematosus
Robinson, G., Wilkinson, M. G. L., & Wincup, C. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.806560 · Cited by 52
Mitochondrial impairment and repair in the pathogenesis of systemic lupus erythematosus
Zhao, L., Hu, X., Xiao, F., Zhang, X., Zhao, L., & Wang, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.929520 · Cited by 54
Talabér, G., Miklóssy, G., Oaks, Z., Liu, Y., Tooze, S. A., Chudakov, D. M., Bánki, K., & Perl, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084392 · Cited by 52
Self-citationMetabolic Targets for Treatment of Autoimmune Diseases
Piranavan, P., Bhamra, M. S., & Perl, A. (2020) · Immunometabolism · doi:10.20900/immunometab20200012 · Cited by 55
Self-citationEmerging Concepts of Nanobiotechnology in mRNA Delivery
Wang, Y., & Yu, C. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.202003545 · Cited by 54
Thioredoxin-1 improves the immunometabolic phenotype of antitumor T cells
Chakraborty, P., Chatterjee, S., Kesarwani, P., Thyagarajan, K., Iamsawat, S., Dalheim, A. V., Nguyen, H. D., Selvam, S. P., Nasarre, P., Scurti, G. M., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006753 · Cited by 52
Advances in the treatment of systemic lupus erythematosus
Scherlinger, M., Kolios, A. G. A., Kyttaris, V. C., & Tsokos, G. C. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01242-0 · Cited by 50
Metabolic determinants of lupus pathogenesis
Teng, X., Brown, J., Choi, S., Li, W., & Morel, L. M. (2020) · Immunological Reviews · doi:10.1111/imr.12847 · Cited by 53
Wang, Y., Song, H., Liu, C., Zhang, Y., Kong, Y., Tang, J., Yang, Y., & Yu, C. (2020) · National Science Review · doi:10.1093/nsr/nwaa268 · Cited by 50
Cellular Trafficking of Nanotechnology‐Mediated mRNA Delivery
Huang, P., Deng, H., Wang, C., Zhou, Y., & Chen, X. S. (2023) · Advanced Materials · doi:10.1002/adma.202307822 · Cited by 53
Updated Review of Complementary and Alternative Medicine Treatments for Systemic Lupus Erythematosus
Greco, C. M., Nakajima, C., & Manzi, S. (2013) · Current Rheumatology Reports · doi:10.1007/s11926-013-0378-3 · Cited by 49
Metabolic dysregulation of lymphocytes in autoimmune diseases
Wang, S., Yang, N., & Zhang, H. (2024) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2024.01.005 · Cited by 49
Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys
Thanou, A., & Merrill, J. T. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2013.145 · Cited by 49
Wu, T., Ye, Y., Min, S., Zhu, J., Khobahy, E., Zhou, J. K., Yan, M., Hemachandran, S., Pathak, S., Zhou, X., et al. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38782 · Cited by 47
Vukelic, M., Li, Y., & Kyttaris, V. C. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02658 · Cited by 47
T Cells in Systemic Lupus Erythematosus
Paredes, J. L., Fernandez‐Ruiz, R., & Niewold, T. B. (2021) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2021.04.005 · Cited by 46
Involvement of trained immunity during autoimmune responses
Mora, V. P., Loaiza, R. A., Soto, J. A., Böhmwald, K., & Kalergis, A. M. (2022) · Journal of Autoimmunity · doi:10.1016/j.jaut.2022.102956 · Cited by 47
Li, J., Wang, Z., Dai, L., Cao, L., Su, J., Zhu, M., Yu, Z., Bai, X., & Ruan, C. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/548085 · Cited by 46
Neutrophils as Drivers of Immune Dysregulation in Autoimmune Diseases with Skin Manifestations
Nakabo, S., Romo‐Tena, J., & Kaplan, M. J. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2021.04.014 · Cited by 45
Anderson, E., Fishbein, J. S., Hong, J., Roeser, J., Furie, R. A., Aranow, C. B., Volpe, B. T., Diamond, B., & Mackay, M. C. (2021) · Lupus Science & Medicine · doi:10.1136/lupus-2021-000559 · Cited by 49
Wilkinson, M. G. L., MOULDING, D. A., McDonnell, T. C. R., Orford, M., Wincup, C., Ting, J. Y. J., Otto, G., Restuadi, R., Kelberman, D., Papadopoulou, C., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/ard-2022-223469 · Cited by 45
Uric acid and kidney damage in systemic lupus erythematosus
dos Santos, M., Veronese, F. V., & Moresco, R. N. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.05.034 · Cited by 45
van Dam, L. S., Rabelink, T. J., van Kooten, C., & Teng, Y. K. O. (2018) · Kidney International Reports · doi:10.1016/j.ekir.2018.11.005 · Cited by 46
Tsai, C., Hsieh, S., Lu, C.-S., Wu, T.-H., Liao, H., Wu, C.-H., Li, K., Kuo, Y., Lee, H.-T., Shen, C., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205183 · Cited by 44
Immunometabolism at the cornerstone of inflammaging, immunosenescence, and autoimmunity in COVID-19
Omarjee, L., Perrot, F., Meilhac, O., Mahé, G., Bousquet, G., & Janin, A. (2020) · Aging · doi:10.18632/aging.202422 · Cited by 43
Liao, P., He, Y., Yang, F., Luo, G., Zhuang, J., Zhai, Z., Zhuang, L., Lin, Z., Zheng, J., & Sun, E. (2018) · Arthritis Research & Therapy · doi:10.1186/s13075-018-1749-y · Cited by 41
Yang, S., Zhang, H., Shi, S., Zhu, Y.-Q., Song, N., Dai, Q., Zhang, W., Gui, M., & Zhang, H. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867326666181126165139 · Cited by 41
Poles, J., Karhu, E., McGill, M., McDaniel, H. R., & Lewis, J. E. (2021) · Journal of Clinical and Translational Research · doi:10.18053/jctres.07.202103.004 · Cited by 42
Ntouros, P. A., Vlachogiannis, N. I., Pappa, M. B., Nezos, A., Mavragani, C. P., Tektonidou, M. G., Souliotis, V. L., & Sfikakis, P. P. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108765 · Cited by 40
Redox mechanisms in autoimmune thyroid eye disease
Buonfiglio, F., Ponto, K. A., Pfeiffer, N., Kahaly, G. J., & Gericke, A. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103534 · Cited by 40
Immunometabolic shifts in autoimmune disease: Mechanisms and pathophysiological implications
Chen, Y., Lin, Q., Cheng, H., Xiang, Q., Zhou, W., Wu, J., & Wang, X. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103738 · Cited by 41
Aging and Systemic Lupus Erythematosus - Immunosenescence and Beyond
van den Hoogen, L. L., Sims, G. P., van Roon, J. A. G., & Fritsch-Stork, R. D. E. (2015) · Current Aging Science · doi:10.2174/1874609808666150727111904 · Cited by 40
Mammalian target of rapamycin as a therapeutic target in osteoporosis
Shen, G., Ren, H. J., Qiu, T., Zhang, Z., Zhao, W., Yu, X., Huang, J., Tang, J., Liang, D., Yao, Z., et al. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.26161 · Cited by 41
The Immunomodulatory Effect of Alpha-Lipoic Acid in Autoimmune Diseases
Liu, W., Shi, L., & Li, S. (2019) · BioMed Research International · doi:10.1155/2019/8086257 · Cited by 40
Metabolite Transporters as Regulators of Immunity
Weiss, H. J., & Angiari, S. (2020) · Metabolites · doi:10.3390/metabo10100418 · Cited by 41
Caza, T. N., Wijewardena, C., Al-Rabadi, L. F., & Perl, A. (2022) · Translational research · doi:10.1016/j.trsl.2022.03.004 · Cited by 40
Self-citationHallmarks of cancer and hallmarks of aging
Blagosklonny, M. V. (2022) · Aging · doi:10.18632/aging.204082 · Cited by 43
Montano, E. N., Bose, M., Huo, L., Tumurkhuu, G., Santos, G. D. L., Simental, B., Stotland, A. B., Wei, J., Merz, C. N. B., Suda, J., et al. (2023) · Arthritis & Rheumatology · doi:10.1002/art.42724 · Cited by 40
Wang, G., Wang, J., Ma, H., Ansari, G. A. S., & Khan, M. F. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.08.020 · Cited by 39
TCR-α/β CD4− CD8− double negative T cells arise from CD8+ T cells
Rodríguez‐Rodríguez, N., Flores-Mendoza, G., Apostolidis, S. A., Rosetti, F., Tsokos, G. C., & Crispín, J. C. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.1ab0120-548r · Cited by 39
Immunometabolism in the pathogenesis of systemic lupus erythematosus
Zhang, C., Wang, H., Yin, L., Mao, Y., & Zhou, W. (2020) · Journal of Translational Autoimmunity · doi:10.1016/j.jtauto.2020.100046 · Cited by 41
Geier, C., & Perl, A. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102984 · Cited by 40
Self-citationImmunometabolism of Tregs: mechanisms, adaptability, and therapeutic implications in diseases
Lu, Y., Wang, Y., Ruan, T., Wang, Y., Ju, L., Zhou, M., Liu, L., Dengfu, Y., & Yao, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1536020 · Cited by 39
Cava, A. L. (2018) · Current Rheumatology Reports · doi:10.1007/s11926-018-0714-8 · Cited by 38
Metabolic regulation of pathogenic autoimmunity: therapeutic targeting
Teng, X., Cornaby, C., Li, W., & Morel, L. M. (2019) · Current Opinion in Immunology · doi:10.1016/j.coi.2019.07.001 · Cited by 38
Systemic lupus erythematosus: An update for ophthalmologists
Papagiannuli, E., Rhodes, B., Wallace, G. R., Gordon, C., Murray, P. I., & Denniston, A. K. (2015) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2015.06.003 · Cited by 39
The emerging role of neutrophil extracellular traps in autoimmune and autoinflammatory diseases
Zeng, L., Xiang, W., Xiao, W., Wu, Y., & Sun, L. (2025) · MedComm · doi:10.1002/mco2.70101 · Cited by 37
Mechanistic aspects of epigenetic dysregulation in SLE
Hedrich, C. M. (2018) · Clinical Immunology · doi:10.1016/j.clim.2018.02.002 · Cited by 37
Low Production of Reactive Oxygen Species Drives Systemic Lupus Erythematosus
Urbonaviciute, V., Luo, H., Sjöwall, C., Bengtsson, A. A., & Holmdahl, R. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.06.001 · Cited by 37
Wang, H., Wang, G., Liang, Y., Du, X., Boor, P. J., Sun, J., & Khan, M. F. (2019) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2019.08.014 · Cited by 37
Metabolic Fitness of T Cells in Autoimmune Disease
Wu, B., Goronzy, J. J., & Weyand, C. M. (2020) · Immunometabolism · doi:10.20900/immunometab20200017 · Cited by 37
Neutrophil, NETs and Behçet's disease: A review
Joncour, A. L., Cacoub, P., Boulaftali, Y., & Saadoun, D. (2023) · Clinical Immunology · doi:10.1016/j.clim.2023.109318 · Cited by 36
Vukelic, M., Kono, M., & Tsokos, G. C. (2020) · Immunometabolism · doi:10.20900/immunometab20200009 · Cited by 36
Zhao, L., Zhou, X., Zhou, X., Wang, H., Gu, L., Ke, Y., Zhang, M., Ji, X., & Yang, X. (2020) · Cytokine · doi:10.1016/j.cyto.2020.155119 · Cited by 36
Reactive oxygen species: The Yin and Yang in (auto-)immunity
Scherlinger, M., & Tsokos, G. C. (2021) · Autoimmunity Reviews · doi:10.1016/j.autrev.2021.102869 · Cited by 38
Metabolic pathways mediate pathogenesis and offer targets for treatment in rheumatic diseases
Wyman, B., & Perl, A. (2019) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000687 · Cited by 35
Self-citationImmunometabolism in the pathogenesis of systemic lupus erythematosus: an update
Romo‐Tena, J., & Kaplan, M. J. (2020) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000738 · Cited by 35
The Ups and Downs of Metabolism during the Lifespan of a T Cell
Balyan, R., Gautam, N., & Gascoigne, N. R. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21217972 · Cited by 36
mRNA delivery via non-viral carriers for biomedical applications
Shuai, Q., Zhu, F., Zhao, M., & Yan, Y. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.121020 · Cited by 35
N-acetylcysteine stimulates protein synthesis in enterocytes independently of glutathione synthesis
Yi, D., Hou, Y., Wang, L., Long, M., Hu, S., Mei, H., Yan, L., Hu, C. A., & Wu, G. (2015) · Amino Acids · doi:10.1007/s00726-015-2105-z · Cited by 35
Amino Acid Metabolism in Lupus
Kono, M., Yoshida, N., & Tsokos, G. C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.623844 · Cited by 36
MTOR Signaling and Metabolism in Early T Cell Development
Werlen, G., Jain, R., & Jacinto, E. (2021) · Genes · doi:10.3390/genes12050728 · Cited by 35
Yoon, N., Jang, A.-K., Seo, Y., & Jung, B. H. (2021) · Metabolites · doi:10.3390/metabo11120812 · Cited by 37
Lu, Z., Tian, Y., Bai, Z., Liu, J., Zhang, Y., Qi, J., Jin, M., Zhu, J., & Li, X. (2022) · Arthritis Research & Therapy · doi:10.1186/s13075-022-02731-y · Cited by 34
Mitochondrial Dysfunction in Systemic Lupus Erythematosus: Insights and Therapeutic Potential
Poznyak, A. V., Orekhov, N. A., Churov, A. V., Starodubtseva, I. A., Beloyartsev, D. F., Kovyanova, T. I., Sukhorukov, V. N., & Orekhov, A. N. (2024) · Diseases · doi:10.3390/diseases12090226 · Cited by 33
Systemic lupus erythematosus: review of synthetic drugs
Tsang-A-Sjoe, M. W. P., & Bultink, I. E. M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1101448 · Cited by 33
Abbasifard, M., Khorramdelazad, H., Rostamian, A., Rezaeian, M., Saeed-Askari, P., Sharifi, G. T. K., Kardoust, M., Sharifi, M. T. K., & Najafizadeh, S. R. (2023) · Trials · doi:10.1186/s13063-023-07083-9 · Cited by 33
Relationship Between Redox Status and Cell Fate in Immunity and Autoimmunity
Ortona, E., Maselli, A., Delunardo, F., Colasanti, T., Giovannetti, A., & Pierdominici, M. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5752 · Cited by 33
The role of mitochondrial dysfunction in kidney injury and disease
Jia, X., Zhu, L., Zhu, Q., & Zhang, J. (2024) · Autoimmunity Reviews · doi:10.1016/j.autrev.2024.103576 · Cited by 34
Tan, M. K. X., Heng, T. Y. J., & Mak, A. (2019) · Cells · doi:10.3390/cells8040323 · Cited by 32
Lepelley, A., Wai, T., & Crow, Y. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.729763 · Cited by 33
New insights into the metabolism of Th17 cells
Kono, M. (2022) · Immunological Medicine · doi:10.1080/25785826.2022.2140503 · Cited by 33
T-cell involvement in sex differences in blood pressure control
Crislip, G. R., & Sullivan, J. C. (2016) · Clinical Science · doi:10.1042/cs20150620 · Cited by 32
Oxidative Stress in SLE T Cells, Is NRF2 Really the Target to Treat?
Ohl, K., & Tenbrock, K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.633845 · Cited by 31
Immune Cell Metabolism in Systemic Lupus Erythematosus
Choi, S., Titov, A. A., Sivakumar, R., Li, W., & Morel, L. M. (2016) · Current Rheumatology Reports · doi:10.1007/s11926-016-0615-7 · Cited by 32
Horisberger, A., Courvoisier, D. S., & Ribi, C. (2019) · Arthritis Research & Therapy · doi:10.1186/s13075-019-1864-4 · Cited by 31
Oxidative stress and Treg depletion in lupus patients with anti-phospholipid syndrome
Lai, Z., Marchena, I., & Perl, A. (2015) · Clinical Immunology · doi:10.1016/j.clim.2015.03.024 · Cited by 31
Self-citationKaplan, M. J. (2024) · Arthritis & Rheumatology · doi:10.1002/art.43019 · Cited by 30
Deconvoluting the heterogeneity of SLE: The contribution of ancestry
Owen, K. A., Grammer, A. C., & Lipsky, P. E. (2021) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2021.11.005 · Cited by 30
Shimojima, Y., Kishida, D., Ichikawa, T., Takamatsu, R., Nomura, S., & Sekijima, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.789740 · Cited by 30
Tsikas, D., & Mikuteit, M. (2022) · Amino Acids · doi:10.1007/s00726-022-03185-x · Cited by 30
mTOR signaling: A pivotal player in Treg cell dysfunction in systemic lupus erythematosus
Zhao, X., Wang, S., Wang, S., Xie, J., & Cui, D. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109153 · Cited by 36
Metabolism of T Lymphocytes in Health and Disease
Gaber, T., Chen, Y., Krauß, P.-L., & Buttgereit, F. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.06.002 · Cited by 32
A cellular overview of immunometabolism in systemic lupus erythematosus
Psarras, A., & Clarke, A. J. (2023) · Oxford Open Immunology · doi:10.1093/oxfimm/iqad005 · Cited by 29
Pathak, S., Stern, C., & Vambutas, A. (2015) · Immunologic Research · doi:10.1007/s12026-015-8696-3 · Cited by 29
Why targeted therapies are necessary for systemic lupus erythematosus
Durcan, L., & Petri, M. (2016) · Lupus · doi:10.1177/0961203316652489 · Cited by 29
SLE-Associated Defects Promote Altered T Cell Function
Crispín, J. C., Hedrich, C. M., Suárez‐Fueyo, A., Comte, D., & Tsokos, G. C. (2017) · Critical Reviews in Immunology · doi:10.1615/critrevimmunol.2018025213 · Cited by 29
Double-Negative T (DNT) Cells in Patients with Systemic Lupus Erythematosus
Poddighe, D., Dossybayeva, K., Kozhakhmetov, S., Розенсон, Р., & Assylbekova, M. (2024) · Biomedicines · doi:10.3390/biomedicines12010166 · Cited by 28
Immmunometabolism of systemic lupus erythematosus
Furment, M. M., & Perl, A. (2024) · Clinical Immunology · doi:10.1016/j.clim.2024.109939 · Cited by 28
Self-citationRedox Pathogenesis in Rheumatic Diseases
Laniak, O. T., Winans, T., Patel, A., Park, J. S., & Perl, A. (2024) · ACR Open Rheumatology · doi:10.1002/acr2.11668 · Cited by 28
Self-citationFerroptosis: A potential therapeutic target in autoimmune disease (Review)
Shen, L., Wang, X., Zhai, C., & Chen, Y. (2023) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2023.12067 · Cited by 27
Metadata
- Authors
- Lai, Z., Hanczko, R., Bonilla, E., Caza, T. N., Clair, B., Bartos, A., Miklossy, G., Jimah, J., Doherty, E., Tily, H., Francis, L., Garcia, R., Dawood, M., Yu, J., Ramos, I., Coman, I., Faraone, S. V., Phillips, P. E., & Perl, A.
- Affiliations
- SUNY Upstate Medical University (US)
- ORCID
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2012-08-27
- Volume
- 64
- Issue
- 9
- Pages
- 2937-2946
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- PMC
- PMC3411859
- OpenAlex
- W2015010210
- Cited by
- 428
- References
- 32
- Citations by year
- 2026: 29 · 2025: 31 · 2024: 39 · 2023: 35 · 2022: 36 · 2021: 40 · 2020: 42 · 2019: 36 · 2018: 45 · 2017: 16 · 2016: 25 · 2015: 23 · 2014: 11 · 2013: 17 · 2012: 3
- FWCI
- 13.22
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Arthritis & Rheumatism (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (AI072648, R01AI072648)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (U01AR076092)
- National Center for Complementary and Integrative Health (AT-004332, R01AT004332)
- Topics
- Health Sciences › Medicine › Rheumatology › Systemic Lupus Erythematosus Research
- Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Keywords
- systemic lupus erythematosus, N-acetylcysteine, glutathione precursor, mTOR inhibition, T cell dysfunction, mitochondrial membrane potential, disease activity, fatigue, apoptosis, CD4+CD8+ T cells, drug safety and tolerability, immunomodulatory therapy, SLEDAI, BILAG index, Fatigue Assessment Scale
- MeSH terms
- Acetylcysteine, Adult, Double-Blind Method, Female, Humans, Lupus Erythematosus, Systemic, Male, Middle Aged, Pilot Projects, Placebos, Severity of Illness Index, T-Lymphocytes, Free Radical Scavengers, Treatment Outcome, Membrane Potential, Mitochondrial, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
